LAWRENCE, Kan.--(BUSINESS WIRE)--Endpoints News, the biopharma industry’s source for breaking news, exclusive reporting and smart analysis, today unveiled this year’s Endpoints 11 winners — honoring the most exciting biotech startups of 2024.
This year’s list includes several artificial intelligence startups trying to reinvent drug R&D, though doing so with very different approaches. It highlights the growth of China’s biotech industry, despite the country’s tensions with the US. Four of the winners are taking new approaches to huge disease categories including inflammation and immunology, obesity and neuroscience. And others are working on advanced technologies for rare ailments, operating at the forefront of editing biology.
“We spent days debating dozens of finalists from around the globe. This year’s group of Endpoints 11 winners represents some of the biggest and most interesting bets happening in biotech,” said Endpoints News Executive Editor Drew Armstrong.
The winners of the 2024 Endpoints 11 awards are:
- Lifordi Immunotherapeutics
- Mirador Therapeutics
- Formation Bio
- Xaira Therapeutics
- MediLink Therapeutics
- Iambic Therapeutics
- Ascidian Therapeutics
- Capstan Therapeutics
- Seaport Therapeutics
- Metsera
- Cardurion Pharmaceuticals
Winners of the awards were honored last night at a ceremony in Boston. Full profiles on the winners were published this morning on endpts.com and are available here. A look back at the outcomes of Endpoints’ prior picks, including IPOs and M&A exits, is available here.
About Endpoints
Endpoints News is the biopharma industry’s trusted news authority. As part of the Financial Times’ FT Specialist group, Endpoints publishes daily newsletters, delivers top-tier reporting on its website, hosts industry-leading events and builds products connecting and informing sophisticated business audiences. For more information, visit www.endpts.com.
